EMEA-001050-PIP02-18-M01

Key facts

Invented name
Taltz
Active substance
ixekizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0280/2019
PIP number
EMEA-001050-PIP02-18-M01
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Eli Lilly Nederland B.V.

E-mail: EU_paediatric@lilly.com
Tel.  +44 1276483000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating